GLMD News and Press, Galmed Pharmaceuticals Ltd.

2026-01-30 16:29:40 ET More on Galmed Seeking Alpha’s Quant Rating on Galmed Historical earnings data for Galmed Financial information for Galmed Read the full article on Seeking Alpha For further details see: Galmed Pharmaceuticals receive...

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire TEL AVIV, Israel , Jan. 30, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiom...

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting PR Newswire Late Breaking Abstract titled " Targeting SCD1 enhances activity of standard of care regorafenib in hepatocellular carcinoma: translational rationale for a phase 1/2 study ...

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH PR Newswire The new patent granted in South Korea is added to earlier patents already granted by the United States Patent and Trademark Office (U...

Galmed Issues CEO Letter to Shareholders PR Newswire TEL AVIV, Israel , Dec. 1, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal onco...

2025-11-26 08:36:57 ET More on Galmed Seeking Alpha’s Quant Rating on Galmed Historical earnings data for Galmed Financial information for Galmed Read the full article on Seeking Alpha For further details see: Galmed GAAP EPS of -$0.33 beat...

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update PR Newswire TEL AVIV, Israel , Nov. 26, 2025 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical compan...

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine PR Newswire The top-line results showed that bioavailability of Aramchol meglumine 400mg and 200mg granules is considerably greater, higher by 5-fold and 3-fold respectively, that of the Aramchol f...

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro PR Newswire The top-line results from the study showed that the 3-drugs' synergistic effect ...

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update PR Newswire TEL AVIV, Israel , Aug. 28, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutic...